SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of:
- Adult patients with genotype 1, 2, 3 or 4 chronic hepatitis C virus
(HCV) infection without cirrhosis or with compensated cirrhosis as a
component of a combination antiviral treatment regimen.
- Pediatric patients 12 years of age and older or weighing at least 35
kg with genotype 2 or 3 chronic HCV infection without cirrhosis or
with compensated cirrhosis in combination with ribavirin.
Is this drug, a contraindication in cirrhosis, pharmacokinetically speaking?